-
公开(公告)号：US20250049910A1
公开(公告)日：2025-02-13
申请号：US18706648
申请日：2022-11-03
Inventor： Peter Ebert , Agnete Fredriksen , Mark Klinger , Gunnstein Norheim , Edward Osborne , Monika Sekelja , Thomas Snyder , Elisabeth Stubsrud
IPC: A61K39/215 , C07K14/005
Abstract: This invention relates to immunogenic constructs, such as polynucleotides, polypeptides and multimeric proteins and to antigenic units and to pharmaceutical compositions/vaccines comprising such immunogenic constructs or antigenic units, which are useful for the prophylactic and therapeutic treatment of diseases caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), as well as methods for producing and using the immunogenic constructs, antigenic units and pharmaceutical compositions/vaccines.
-
公开(公告)号：US11479605B2
公开(公告)日：2022-10-25
申请号：US16784778
申请日：2020-02-07
Applicant: Nykode Therapeutics ASA
Inventor： Pier Adelchi Ruffini , Bjarne Bogen , Agnete Brunsvik Fredriksen
IPC: C07K16/28 , A61K39/00 , C07K16/44 , A61K39/145 , A61K39/12
Abstract: The present invention relates to novel recombinant fusion proteins, such as human antibody-based molecules called Vaccibodies, which are able to trigger both a T cell- and B cell immune response. The present invention also relates to a method of treating a cancer or an infectious disease by means of these specific fusion proteins.
-
公开(公告)号：US20230303718A1
公开(公告)日：2023-09-28
申请号：US18163484
申请日：2023-02-02
Applicant: NYKODE THERAPEUTICS ASA
Inventor： Bjarne BOGEN , Agnete Brunsvik FREDRIKSEN , Inger SANDLIE
IPC: C07K16/44 , C07K16/28 , C07K14/005 , C07K14/34 , C07K14/705 , C07K14/715 , C12N9/12
CPC classification number: C07K16/44 , C07K16/2833 , C07K14/005 , C07K14/34 , C07K14/70578 , C07K14/7158 , C07K16/28 , C12N9/1276 , A61K2039/505
Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
-
公开(公告)号：US20230293650A1
公开(公告)日：2023-09-21
申请号：US17995780
申请日：2021-04-09
Applicant: Nykode Therapeutics ASA
Inventor： Agnete Brunsvik Fredriksen , Monika Sekelja , Karoline Schjetne , Stine Granum
CPC classification number: A61K39/0011 , A61P35/00 , A61K2039/53 , A61K2039/6031 , A61K2039/70
Abstract: The present invention relates to an individualized therapeutic anticancer vaccine, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine.
-
公开(公告)号：US20240350601A1
公开(公告)日：2024-10-24
申请号：US18738685
申请日：2024-06-10
Applicant: Nykode Therapeutics ASA
Inventor： Stine Granum , Elisabeth Stubsrud , Agnete Brunsvik Fredriksen
CPC classification number: A61K39/0011 , A61P35/00 , A61K2039/53 , A61K2039/6031 , A61K2039/6056 , A61K2039/627 , A61K2039/64 , A61K2039/70
Abstract: The present invention relates to an anticancer vaccine which includes polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine includes a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit. The antigenic unit includes from 3 to 50 antigenic subunits separated by a second linker with each antigenic subunit having at least a part of a cancer neoepitope sequence. The vaccine can include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide.
-
Patent Agency Ranking
公开(公告)号：US20240325526A1
公开(公告)日：2024-10-03
申请号：US18751098
申请日：2024-06-21
Applicant: Nykode Therapeutics ASA
Inventor： Jeroen VAN BERGEN , Gerben Carolus Martinus ZONDAG
CPC classification number: A61K39/39 , A61K2039/55516 , A61K2039/55527
Abstract: The invention relates to a constitutively active pro-inflammatory caspase, comprising shuffled p10 and p20 domains, for use in a method of stimulating an immune response in an individual. The invention further relates to an immune-stimulating composition, comprising said constitutively active pro-inflammatory caspase, comprising shuffled p10 and p20 domains and a pharmacologically acceptable excipient, and its use in a method of treating an individual.
-
公开(公告)号：US20240252625A1
公开(公告)日：2024-08-01
申请号：US18560868
申请日：2022-05-10
Applicant: Nykode Therapeutics ASA
CPC classification number: A61K39/35 , A61K39/0008 , A61K45/06 , A61P37/06 , C12N15/86 , C12N2800/107 , C12N2800/60 , C12N2810/851 , C12N2840/206
Abstract: The present invention relates to vectors, such as DNA plasmids, comprising multiple nucleic acid sequences engineered to be co-expressed as separate molecules. Such separate molecules include a first polypeptide, wherein the first polypeptide comprises a targeting unit that targets antigen-presenting cells, a multimerization unit, such as dimerization unit, and an antigenic unit comprising one or more T cell epitopes of a self-antigen, an allergen, an alloantigen or a xenoantigen, and one or more immunoinhibitory compounds
-
公开(公告)号：US12059459B2
公开(公告)日：2024-08-13
申请号：US17557988
申请日：2021-12-21
Applicant: Nykode Therapeutics ASA
Inventor： Stine Granum , Elisabeth Stubsrud , Agnete Brunsvik Fredriksen
CPC classification number: A61K39/0011 , A61P35/00 , A61K2039/53 , A61K2039/6031 , A61K2039/6056 , A61K2039/627 , A61K2039/64 , A61K2039/70
Abstract: The present invention relates to an anticancer vaccine which includes polynucleotides or polypeptides, methods of treatment of cancer wherein such an anticancer vaccine is used as well as methods for producing the vaccine. The vaccine includes a polynucleotide with a nucleotide sequence encoding a targeting unit, a dimerization unit, a first linker and an antigenic unit. The antigenic unit includes from 3 to 50 antigenic subunits separated by a second linker with each antigenic subunit having at least a part of a cancer neoepitope sequence. The vaccine can include a polypeptide encoded by the polynucleotide or a dimeric protein with two polypeptides encoded by the polynucleotide.
-
公开(公告)号：US20240132596A1
公开(公告)日：2024-04-25
申请号：US18469961
申请日：2023-09-18
Applicant: UNIVERSITY OF OSLO , Nykode Therapeutics ASA
Inventor： Gunnveig Grodeland , Bjarne Bogen , Agnete B. Fredriksen
CPC classification number: C07K16/2833 , A61K39/00 , A61K39/12 , A61K39/39 , C07K16/34 , C07K16/46 , C07K2317/53 , C07K2317/55 , C07K2317/622
Abstract: The present invention relates to an immunoglobulin derived single-chain fragment variable (scFv) that broadly binds HLA II molecules and uses thereof. In particular, targeting of an antigen to antigen presenting cells with the HLAII-specific targeting unit provided herein find use in enhancing immune responses after vaccination.
-
公开(公告)号：US20230165952A1
公开(公告)日：2023-06-01
申请号：US17997407
申请日：2021-05-03
Applicant: Nykode Therapeutics ASA
Inventor： Agnete Brunsvik Fredriksen , Monika Sekelja , Karoline Schjetne , Gunnstein Norheim , Elisabeth Stubsrud
IPC: A61K39/215 , A61P31/14
CPC classification number: A61K39/215 , A61P31/14 , A61K2039/6075
Abstract: Disclosed is a vaccine comprising an immunologically effective amount of a polynucleotide comprising a nucleotide sequence encoding a targeting unit, a dimerization unit and an antigenic unit, wherein the antigenic unit comprises at least one betacoronavirus epitope. The vaccine is ideal for pandemic and epidemics as it can induce rapid, strong immune response with lower/fewer doses because the antigen is targeted to antigen presenting cells and the antigen is produced in the body.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.016 seconds)
